Penile Cancer Treatment in India

Expert penile cancer treatment in India — organ-preserving surgery, Mohs surgery, brachytherapy, and inguinal lymph node management. Prioritizing function alongside cure.

Estimated cost: $4,000 – $8,000 · Average stay: 5–8 days

Penile cancer is a rare malignancy, representing less than 1% of cancers in men in developed countries but having higher incidence in parts of Africa, Asia, and South America. In India, penile cancer accounts for approximately 4–10% of male genitourinary malignancies due to high rates of phimosis (inability to retract the foreskin) and lower circumcision rates. HPV infection — particularly HPV-16 — is implicated in the majority of penile squamous cell carcinomas.

Modern treatment of penile cancer has shifted dramatically toward organ preservation. Early-stage tumors (T1–T2) can be effectively managed with organ-preserving approaches — laser therapy, wide local excision, glansectomy, or partial penectomy — without compromising cancer control. Total penectomy, which was once the default approach for most penile cancers, is now reserved for large or proximally located tumors where organ preservation would leave inadequate surgical margins.

Radiation therapy — external beam radiation or brachytherapy (internal radiation delivered by needles implanted into the penis) — provides excellent local control for selected T1–T2 tumors with complete organ preservation, though requiring highly specialized expertise.

The management of regional lymph nodes — the inguinal lymph nodes — is a critical component of penile cancer treatment. Inguinal lymph node metastasis is present in approximately 30–40% of cases, and node-positive patients benefit from complete inguinal and pelvic lymph node dissection with adjuvant chemotherapy.

India's urologic oncology centers offer comprehensive penile cancer management, including all organ-preserving surgical options and specialized inguinal lymph node dissection.

Types and Stages of Penile Cancer

Squamous cell carcinoma accounts for over 95% of penile cancers. Subtypes include basaloid and warty SCC (HPV-driven), and keratinizing SCC (non-HPV, associated with phimosis and lichen sclerosus).

AJCC staging:

• Tis (Carcinoma in situ, Bowen's disease / Erythroplasia of Queyrat): non-invasive. Topical treatment or laser.
• T1a: Tumor invades subepithelial connective tissue, grade 1–2, no lymphovascular invasion. Low risk.
• T1b: Grade 3 or lymphovascular invasion present. High risk despite superficial invasion.
• T2: Tumor invades corpus spongiosum. Wide excision or partial penectomy.
• T3: Tumor invades corpus cavernosum. Partial or total penectomy depending on extent.
• T4: Adjacent structure invasion. Total penectomy; neoadjuvant chemotherapy considered.

Lymph node staging: sentinel lymph node biopsy is recommended for all T1b and above tumors to detect occult nodal metastasis — present in approximately 20–25% of clinically N0 patients with these T stages.

Who Is a Candidate for Penile Cancer Treatment?

All patients with confirmed penile cancer require treatment. The approach depends strongly on tumor stage, grade, and location.

Carcinoma in situ candidates: Tis can be treated with topical 5-FU cream, imiquimod, glans resurfacing (laser or surgical), or circumcision for preputial involvement.

Organ-preserving surgery candidates: T1–T2 tumors with adequate disease-free margins achievable without sacrifice of the entire glans or penis. Options include: wide local excision (for small T1 tumors), glansectomy (removal of the glans with penile head reconstruction — preserving penile length and urinary function), or partial penectomy with at least 5 mm surgical margin.

Brachytherapy candidates: T1–T2 tumors ≤4 cm on the glans or distal shaft in patients suitable for implant under anesthesia. Brachytherapy achieves local control rates of 70–80% with complete organ preservation. Requires specialized radiation oncology expertise with penile brachytherapy experience.

Inguinal lymph node dissection candidates: all T1b and above tumors require sentinel node biopsy or modified inguinal lymphadenectomy. Clinically involved nodes require complete inguinal + pelvic lymph node dissection and neoadjuvant or adjuvant TIP chemotherapy (paclitaxel + ifosfamide + cisplatin).

Penile Cancer Surgery and Lymph Node Management

Organ-preserving surgery is the standard approach for all eligible tumors. Glansectomy — removal of the glans (head) of the penis with split-thickness skin graft reconstruction — achieves excellent functional and oncologic outcomes for T1–T2 glans tumors, maintaining urinary and sexual function and penile length.

Partial penectomy: removes the distal portion of the penis with a 5 mm clear margin. Urination remains possible through the reconstructed meatus. Sexual function is partially preserved depending on remaining penile length. Preferred for larger T2 or proximal shaft tumors where glansectomy is insufficient.

Sentinel lymph node biopsy (SLNB): using blue dye and radiotracer injected around the penile tumor, the sentinel lymph nodes in the inguinal region are identified and removed. If positive, complete inguinal lymph node dissection is performed. SLNB avoids the significant morbidity (lymphedema, wound breakdown) of full inguinal dissection in the 75–80% of patients who are node-negative.

TIP chemotherapy (paclitaxel + ifosfamide + cisplatin) for node-positive or locally advanced disease: 4 cycles neoadjuvant before lymphadenectomy, or adjuvant after lymphadenectomy in patients with pathologically confirmed pelvic node involvement.

Procedure Steps

1. Penile biopsy: excisional or incisional under local anesthesia for accurate histological diagnosis and grading.
2. Staging: MRI penis for T staging; CT pelvis/abdomen for lymph node assessment; PET-CT for clinically node-positive disease.
3. Multidisciplinary urology oncology tumor board: urologist + radiation oncologist.
4. Circumcision first if phimosis present — allows full tumor visualization and improves radiation eligibility.
5. Organ-preserving surgery: glansectomy or wide local excision with intraoperative frozen section margin control.
6. Sentinel lymph node biopsy (T1b and above) or modified inguinal lymphadenectomy.
7. For node-positive disease: complete inguinal + pelvic lymphadenectomy + TIP chemotherapy.
8. Surveillance: penoscopy every 3 months for 2 years; MRI every 6 months.

Penile Cancer Treatment Approaches

Glansectomy + Skin Graft Reconstruction

Removal of the entire glans with replacement by split-thickness skin graft from the thigh or groin. Preserves penile length and urinary function. Oncologically equivalent to partial penectomy for T1–T2 glans tumors. Achieves local recurrence rates of 5–10% at specialized centers.

Cost: $4,000 – $8,000

Brachytherapy (Interstitial Radiation)

Radioactive iridium-192 needles implanted around the penile tumor under anesthesia, delivering focused radiation over 4–6 days. Complete organ preservation. Local control rates of 70–80% for T1–T2 tumors ≤4 cm. Requires specialized brachytherapy expertise — available at select Indian cancer centers.

Cost: $3,500 – $7,000 (full course)

Sentinel Lymph Node Biopsy (SLNB)

Minimally invasive lymph node staging using blue dye and radiotracer to identify and remove sentinel nodes. Avoids complete inguinal dissection and its morbidity (lymphedema, wound breakdown) in node-negative patients. Sensitivity of 90%+ in experienced hands.

Cost: $2,000 – $4,000 (bilateral)

TIP Chemotherapy (Node-Positive)

Paclitaxel + ifosfamide + cisplatin chemotherapy for lymph node-positive or locally advanced penile cancer. Given as 4 cycles neoadjuvant before lymphadenectomy or adjuvant after. Achieves objective response in 50%+ of node-positive patients.

Cost: $1,500 – $3,500 per cycle

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

India — $4,000 – $8,000 — Save 65–75%

UAE — $7,000 – $13,000 — Save 50–60%

USA / UK — $15,000 – $35,000+ — Baseline

Penile cancer treatment in India provides expert organ-preserving surgery and complete inguinal lymph node management at 65–75% lower cost than Western countries. India's urologic oncologists, experienced through higher disease volume, bring specialized expertise in organ-preserving approaches — glansectomy, SLNB — that may be performed less frequently at smaller Western centers.

Recovery & Follow-up

After glansectomy with skin graft, a urethral catheter is maintained for 2–3 weeks while the graft incorporates. Hospital stay is 3–5 days. Graft take is confirmed at the 3-week check; urination through the reconstructed meatus begins after catheter removal. After inguinal lymph node dissection, drain tubes are maintained until output decreases — typically 5–7 days. Lymphedema of the legs is a long-term risk and managed with compression stockings and physiotherapy.

Recovery Tips

• Follow strict wound care instructions after glansectomy — keeping the graft site clean and immobile promotes optimal healing.
• Compression stockings should be worn from the day of inguinal lymphadenectomy — this prevents lymphedema.
• HPV vaccination (if under 45 and not previously vaccinated) reduces risk of cancer in the remaining normal tissue.
• Attend all surveillance penoscopy appointments — local recurrence after organ-preserving surgery can be managed with further limited excision.
• Report any new penile nodules, swelling of the groin, or skin changes promptly.

Risks & Complications

Glansectomy risks include skin graft failure (5–10%), urethral stricture, and cosmetic outcome. Partial penectomy affects sexual function proportionally to resection extent. Inguinal lymphadenectomy risks include lymphedema of the legs (20–30% long-term), wound breakdown (10–15%), and deep vein thrombosis. Brachytherapy risks include urethral stricture (10–20%), radionecrosis (5%), and local recurrence. TIP chemotherapy causes significant nausea, alopecia, and neutropenia.

Why GAF Healthcare

Gaf Healthcare connects penile cancer patients with India's specialized urologic oncology programs, where experienced urologists perform the full spectrum of organ-preserving techniques — glansectomy, SLNB — and complex inguinal lymph node dissection. We ensure patients are evaluated by specialists with high caseloads, optimizing both oncologic outcomes and functional preservation.

Frequently Asked Questions

What is the survival rate for penile cancer?

Five-year survival by stage: Tis/T1 N0 — 85–95%, T2 N0 — 70–80%, N1 (1 inguinal node) — 60–75%, N2–N3 (multiple nodes) — 20–40%. Nodal status is the single strongest prognostic factor — pathologically node-negative patients have dramatically better outcomes than node-positive patients.

Can penile cancer be treated without removing the penis?

Yes, in most early-stage cases. T1–T2 tumors on the glans are eligible for glansectomy with reconstruction, laser therapy, or brachytherapy — all of which preserve the penis. Total penectomy is reserved for large, proximal, or deeply invasive tumors where organ preservation would leave inadequate surgical margins.

What is sentinel lymph node biopsy for penile cancer?

SLNB identifies the first (sentinel) lymph nodes draining the penile tumor using blue dye and a radioactive tracer. If these nodes are cancer-free, the remaining inguinal nodes are almost certainly clear, avoiding a full inguinal dissection with its significant lymphedema risk. SLNB is recommended for all T1b and higher tumors with clinically negative lymph nodes.

What is penile brachytherapy?

Penile brachytherapy involves implanting radioactive iridium-192 needles into and around the penile tumor under anesthesia, delivering a concentrated radiation dose over 4–6 days. It achieves 70–80% local control for T1–T2 glans tumors ≤4 cm with complete preservation of the penis. It requires specialized brachytherapy expertise and is available at select major Indian cancer centers.

Is HPV vaccination protective against penile cancer?

Yes. HPV (particularly HPV-16) causes approximately 40–50% of penile cancers. HPV vaccination with Gardasil-9 before sexual debut prevents HPV-16 infection and significantly reduces penile cancer risk. Vaccination is recommended for boys and young men up to age 26 in most international guidelines.